Evvy
StreetZero Signal 79
About Evvy
Evvy is a precision women’s health company focused on the vaginal microbiome that launched the first at-home CLIA- and CLEP-certified mNGS vaginal microbiome test in 2021. The company provides clinician-reviewed results and personalized treatment plans while building proprietary data linking vaginal microbes to conditions such as infertility, gynecological cancer, preterm birth, and IVF outcomes. It was founded in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro and is headquartered in New York City.
LATEST FUNDINGSeries B
$40.0M
Announced 2026-09-15
IN THE NEWS
- 🔗 Evvy, Precision Women’s Health Startup focused on the Vaginal Microbiome, Announces $14M Series A - Microbiome Times Magazine
- 🔗 Evvy raises $40M to expand precision medicine for vaginal health
- 🔗 Evvy: Funding, Team & Investors | Startup Intros
- 🔗 Evvy raises $40M as it seeks to further women's health research with ...
- 🔗 Careers | Evvy
EMPLOYEES1-10
FOUNDED2021
HQNew York City, NY, USA
Industry
Women's Health
Tags
Women's HealthVaginal MicrobiomePrecision MedicineSeries B
Investors
Key highlights
- Raised $40 million Series B led by Catalio Capital Management in 2026.
- Operates the only at-home CLIA- and CLEP-certified mNGS vaginal microbiome test.
- Has processed tests for more than 10,000 users and maintains a core team of approximately ten employees.
- Conducting prospective studies in IVF clinics to link microbiome data to fertility outcomes.
- Backed by healthcare-focused investors including General Catalyst and Labcorp Venture Fund.
Ask StreetZero about Evvy
Put our AI to work on this deal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account